Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.

被引：0
|
作者：
Gazzoni, Gabriela
Vilbert, Maysa
Oliveira, Joao Pedro
Dacoregio, Maria Inez
Michelon, Isabella
Reis, Pedro
Braga, Marcelo
Simoes, Clara
Oliveira, Lilia
Cardoso, Ana Paula Garcia
机构：
[1] Hosp Servidor Publ Estadual, Sao Paulo, Brazil
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil
[4] Univ Estadual Ctr Oeste UNICTR, Guarapuava, Brazil
[5] Univ Catolica Pelotas, Pelotas, RS, Brazil
[6] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil
[7] Fac Multivix, Vitoria, Brazil
[8] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[9] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.761
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
    Yajima, Shugo
    Hirose, Kohei
    Masuda, Hitoshi
    JAMA NETWORK OPEN, 2025, 8 (03)
  • [2] Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis
    Wang, Leibo
    Shi, Guanyu
    Zhao, Guoqiang
    He, Wei
    Cen, Zhuangding
    Xu, Feng
    ANTI-CANCER DRUGS, 2023, 34 (04) : 473 - 478
  • [3] Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience
    Vlachou, Evangelia
    Johnson III, Burles Avner
    Mcconkey, David
    Jing, Yuezhou
    Matoso, Andres
    Hahn, Noah M.
    Hoffman-Censits, Jean
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [4] Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature
    Vlachou, Evangelia
    Matoso, Andres
    McConkey, David
    Jing, Yuezhou
    Johnson, Burles Avner
    Hahn, Noah M.
    Hoffman-Censits, Jean
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 49 : 100 - 103
  • [5] Increased risk of hyperglycemia in patients with advanced urothelial cancer treated with enfortumab vedotin: A systematic review and meta-analysis
    Cheng, Ryan
    Boparai, Montek
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    ANTICANCER RESEARCH, 2024, 44 (07) : 3025 - 3032
  • [7] Incidence and risk of peripheral sensory neuropathy with enfortumab vedotin in patients with advanced urothelial cancer: A systematic review and meta-analysis
    Shah, Yousuf
    Sher, Amna Falak
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin
    Nunez, Aurora Ortiz
    Portela, Judit Gonzalez
    Zozaya, Neboa
    Fernandez, Irene
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1222 - 1231
  • [9] Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis
    Khosla, Harshit
    Bhatt, Sita
    Wang, Ming-Jin
    Gignac, Gretchen
    Mittal, Kriti
    Patel, Jasmine
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 941 - 944
  • [10] FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Khalid, Sidra
    Basulaiman, Bassam Mohammed
    Emack, Jeff
    Booth, Christopher M.
    Hernandez-Barajas, David
    Duran, Ignacio
    Smoragiewicz, Martin
    Amir, Eitan
    Vera-Badillo, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345